Victory Capital Management Inc Zymeworks Inc. Transaction History

Victory Capital Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 02, 2021	SELL	$27.35 - $37.28 $1.01 Million - $1.37 Million	-36,810 Closed	0 $0
Q2 2021 Aug 03, 2021	SELL	$26.5 - $38.23 $62,275 - $89,840	-2,350 Reduced 6.0%	36,810 $1.28 Million
Q1 2021 May 04, 2021	SELL	$29.83 - $56.81 $51,904 - $98,849	-1,740 Reduced 4.25%	39,160 $1.24 Million
Q4 2020 Feb 01, 2021	SELL	$39.12 - $54.99 $268,754 - $377,781	-6,870 Reduced 14.38%	40,900 $1.93 Million
Q3 2020 Nov 09, 2020	SELL	$29.21 - $46.58 $698,995 - $1.11 Million	-23,930 Reduced 33.38%	47,770 $2.23 Million
Q2 2020 Aug 07, 2020	SELL	$33.67 - $40.0 $6.02 Million - $7.15 Million	-178,692 Reduced 71.36%	71,700 $2.59 Million
Q1 2020 May 04, 2020	SELL	$24.28 - $49.8 $222,186 - $455,719	-9,151 Reduced 3.53%	250,392 $8.88 Million
Q4 2019 Feb 06, 2020	BUY	$24.84 - $45.46 $38,502 - $70,463	1,550 Added 0.6%	259,543 $11.8 Million
Q4 2019 Feb 04, 2020	BUY	$24.84 - $45.46 $1.54 Million - $2.82 Million	62,003 Added 31.64%	257,993 $11.3 Million
Q3 2019 Nov 12, 2019	BUY	$22.78 - $29.08 $4.46 Million - $5.7 Million	195,990 New	195,990 $4.86 Million

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $949M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.